Corpus overview


Overview

MeSH Disease

Human Phenotype

Cough (12)

Fever (9)

Fatigue (7)

Pneumonia (7)

Anosmia (5)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 29
    records per page




    New onset of Myasthenia Gravis MESHD in a patient with COVID-19: A novel case report and literature review

    Authors: Shitiz Sriwastava; Medha Tandon; Saurabh Kataria; Maha Daimee; Shumaila Sultan

    doi:10.21203/rs.3.rs-77694/v1 Date: 2020-09-14 Source: ResearchSquare

    The novel coronavirus outbreak of SARS-CoV-2 first began in Wuhan, China in December, 2019. The most striking manifestation is atypical pneumonia HP pneumonia MESHD and respiratory complications MESHD, however various neurological manifestations are now well recognized. Currently, there have been a very few case reports in regards to COVID-19 in patients with known history of myasthenia gravis MESHD. Myasthenia gravis MESHD ( MG MESHD) causes muscle weakness HP muscle weakness MESHD, especially respiratory muscles in high-risk COVID-19 patients that can lead to severe respiratory compromise. There are few reported cases of severe myasthenia crisis MESHD following COVID-19, likely due to the involvement of the respiratory apparatus and from use of immunosuppressive medication. We report a first case MG MESHD developing secondary to COVID-19 infection MESHD in a 65-year-old woman. Two weeks prior to hospitalization, the patient suffered from cough HP, fever HP fever MESHD, diarrhea HP diarrhea MESHD and was found to be positive for COVID-19 via nasopharyngeal RT-PCR swab test. The electrodiagnostic test showed decremental response over more than 10% on repetitive nerve stimulation test of orbicularis oculi. She tested positive for antibodies SERO against Acetylcholine receptor (AchR).COVID-19 is known to cause release of inflammatory cytokines leading to immune-mediated damage. MG MESHD is an immune-mediated disorder caused due to molecular mimicry and autoantibodies against the neuromuscular junction. 

    The major predictors of testing positive for COVID-19 among symptomatic hospitalized patients

    Authors: Samson Barasa; David Tarazona; Faviola Valdivia Guerrero; Nancy Rojas Serrano; Dennis Carhuaricra; Lenin Maturrano Hernandez; Ronnie Gavilan Chavez

    doi:10.1101/2020.09.11.20192963 Date: 2020-09-13 Source: medRxiv

    The major predictors of testing positive for COVID-19 among symptomatic hospitalized patients Samson Barasa,1 Amy Ballard,1 Josephine Kiage-Mokaya, 1 Michael Friedlander,1 Geraldine Luna,2 1PeaceHealth Sacred Heart 2University of Illinois at Chicago Introduction: Increasing corona virus disease MESHD 2019 (COVID-19) pre-test probability can minimize testing patients who are less likely to have COVID-19 and therefore reducing personal protective equipment and COVID-19 testing kit use. The aim of this study was to identify patients who were likely to test positive for COVID-19 among symptomatic patients suspected of having COVID-19 during hospitalization by comparing COVID-19 positive and negative patients. Method: We conducted a retrospective chart review of patients who were [≥]18 years old and underwent COVID-19 Polymerase chain reaction test because they presented with symptoms thought to be due to COVID-19. A Poisson regression analysis was conducted after clinical presentation, demographic, medical co-morbidities, laboratory and chest image data was retrieved from the medical records. Results: Charts of 277 and 18 COVID-19 negative and positive patients respectively were analyzed. Dyspnea HP Dyspnea MESHD (61%) was the most common symptom among COVID-19 negative patients, while 72% and 61% COVID-19 positive patients had cough HP cough MESHD and fever HP fever MESHD respectively. COVID-19 positive patients were more likely to present initially with cough HP [1.082 (1.022 - 1.145)], fever HP fever MESHD [1.066 (1.014 - 1.121)] and be 50 to 69 years old [1.094 (1.021 - 1.172)]. Dyspnea HP Dyspnea MESHD, weakness MESHD, lymphopenia HP lymphopenia MESHD and bilateral chest image abnormality were not associated with COVID-19 positivity. COVID-19 positive patients were less likely to have non-COVID-19 respiratory viral illness [1.068 (1.019 - 1.119)], human immunodeficiency HP immunodeficiency MESHD virus [0.849 (0.765 - 0.943)] and heart failure MESHD history [0.093 (0.891 - 0.978)]. Other chronic medical problems ( hypertension HP hypertension MESHD, diabetes mellitus HP diabetes mellitus MESHD, chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD and coronary artery disease MESHD) were not associated with testing positive for COVID-19. Conclusion: Cough HP, fever HP fever MESHD and being 50 to 69 years old are better predictors of symptomatic COVID-19 positivity during hospitalization. Despite published studies reporting a high prevalence SERO of lymphopenia HP lymphopenia MESHD among COVID-19 positive patients, lymphopenia HP lymphopenia MESHD is not associated with the risk of testing positive for COVID-19. Key Words: COVID-19, Predictors, Symptomatic, Hospitalized

    Pesticide use and COVID-19: An Indictment of Global Agriculture and An Advocacy of the Mediterranean Food Culture

    Authors: Wadie Othmani

    doi:10.21203/rs.3.rs-72815/v1 Date: 2020-09-05 Source: ResearchSquare

    As an exploratory and theoretical reflection for future articles discussing the perceived green/health qualities of tunisian food as a tourist promotion argument, the article is based on the assumption that the COVID-19 pandemic would have more impact in countries whose population has an immune system weakened by food overtreated with pesticides, and that the Mediterranean food culture, which offers foods with little or no pesticide treatment, is the best diet to develop the necessary immunity to resist COVID-19 and, by extension, resist other pandemics. To demonstrate this, the thematic map technique was used to cross-reference several masses of official statistical data. The results suggest four main categories of countries in relation to the link between deaths from COVID-19 and the use of pesticides in agriculture. This study demonstrates, therefore, the weakness MESHD, if not the inaccuracy, of certain hypotheses which are circulating or have circulated in recent months and that attempt to explain each country's response to the COVID-19 pandemic. Thus, assumptions such as the role of quarantine in containing the pandemic, the role of the BCG vaccine and the role of heat will prove unreliable. On the other hand, the hypothesis the paper will defend is that of the role of a healthy Mediterranean and flexitarian diet in strengthening the human immune system, which in turn counteracts the SARS-CoV-2 virus. This sanitary suitability would therefore be an argument for promoting and disseminating this culinary heritage throughout the world and thus contribute to its development as a tourist attraction.

    Clinical Characteristics of Coronavirus disease 2019 (COVID-19) Among Patients at a Movement Disorders MESHD Center

    Authors: J. Antonelle de Marcaida; Jeffrey Lahrmann; Duarte Machado; Lawrence Bluth; Michelle Dagostine; Maria Moro-de Casillas; Elena Bortan; Sulada Kanchana; Mark Alberts

    id:10.20944/preprints202008.0618.v1 Date: 2020-08-27 Source: Preprints.org

    It is not established whether SARS-CoV-2 (COVID-19) patients with movement disorders MESHD, are at greater risk for more serious outcomes than the larger COVID-19 population beyond the susceptibility associated with greater age TRANS. We reviewed electronic health records and conducted telephone interviews to collect the demographics and clinical outcomes of patients seen at our Movement Disorders MESHD Center who tested positive for COVID-19 from 8 March 2020 through 6 June 2020. Thirty-six patients were identified, 23 men and 13 women, median age TRANS of 74.5 years. They primarily carried diagnoses of idiopathic Parkinson disease MESHD (n=22; 61%) and atypical parkinsonism HP parkinsonism MESHD (n=7; 19%) with the balance having other diagnoses. Twenty-seven patients (75%) exhibited alteration in mental status and fifteen (42%) had abnormalities of movement HP abnormalities of movement MESHD as common manifestations of COVID-19; in 61% and 31%, these were the presenting symptoms of the disease. 67% of patients in our cohort required hospitalization, and the mortality rate was 39%.. These data demonstrate that in patients with movement disorders MESHD, the likelihood of hospitalization and death MESHD after contracting COVID-19 was substantially greater than in the general population. Patients with movement disorders MESHD frequently presented with altered mental status, generalized weakness MESHD, or worsening mobility but not anosmia HP anosmia MESHD.

    A Young Adult TRANS with COVID-19 and Multisystem Inflammatory Syndrome MESHD in Children TRANS (MIS-C)-like Illness: A Case Report

    Authors: Aaron D. Kofman; Emma K. Sizemore; Joshua F. Detelich; Benjamin Albrecht; Anne L. Piantadosi

    doi:10.21203/rs.3.rs-61906/v1 Date: 2020-08-18 Source: ResearchSquare

    Background: A healthy 25-year-old woman developed COVID-19 disease with clinical characteristics resembling Multisystem Inflammatory Syndrome in Children TRANS (MIS-C), a rare form of COVID-19 described primarily in children TRANS under 21 years of age TRANS.Case Presentation: The patient presented with one week of weakness MESHD, dyspnea HP dyspnea MESHD, and low-grade fevers HP, followed by mild cough HP, sore throat, vomiting HP vomiting MESHD, diarrhea HP diarrhea MESHD, and lymph node swelling MESHD. She was otherwise healthy, with no prior medical history. Her hospital course was notable for profound acute kidney injury HP acute kidney injury MESHD, leukocytosis HP leukocytosis MESHD, hypotension HP hypotension MESHD, and cardiac dysfunction MESHD requiring ICU admission and vasopressor support. MIS-C-like illness secondary to COVID-19 was suspected due to physical exam findings of conjunctivitis HP conjunctivitis MESHD, mucositis MESHD, and shock HP. She improved following IVIG, aspirin, and supportive care, and was discharged on hospital day 5.Conclusion: MIS-C-like illness should be considered in adults TRANS presenting with atypical clinical findings and concern for COVID-19. Further research is needed to support the role of IVIG and aspirin in this patient population.

    A concomitant Guillain-Barre Syndrome with COVID-19: a first case-report in Colombia

    Authors: Nuvia Mackenzie; Eva Lopez-Coronel; Alberto Dau; Dieb Maloof; Salvador Mattar; Jesus Tapia Garcia; Briyis Fontecha; Cristina Lanata; Hernan Felipe Guillen-Burgos

    doi:10.21203/rs.3.rs-61279/v1 Date: 2020-08-17 Source: ResearchSquare

    Background: During the COVID-19 pandemic, different neurological manifestations have been published. However, few cases of Guillain-Barre Syndrome MESHD and COVID-19 have been reported. We describe a concomitant Guillain-Barre Syndrome MESHD and COVID-19 patient.Case presentation: a 39 years old woman was admitted in a teaching hospital in Barranquilla, Colombia with a history of progressive general weakness MESHD with lower limb dominance. A previous symptom as ageusia, anosmia HP anosmia MESHD and intense headache HP headache MESHD was reported. On admission, facial diplegia HP, quadriparesis MESHD with lower limbs predominance and Medical Research Council Scale 2/5 in lower limbs and 4/5 in upper limbs was reported. During clinical evolution, due to general areflexia HP areflexia MESHD, hypertensive emergency MESHD and progressive diaphragmatic weakness HP diaphragmatic weakness MESHD, the patient was admitted to intensive care unit. Cerebrospinal Serum SERO Fluid revealed protein-cytologic dissociation and electromyography test were compatible with Guillain-Barre Syndrome MESHD. By symptoms before hospitalization, SARS-CoV2 diagnostic testing was performed with positive result in second test. Management to COVID-19 and Guillain Barre Syndrome was performed and patient was discharged after 20 days of hospitalization with clinical improvement.Conclusions: Few cases have been published reporting COVID-19 and Guillain-Barre Syndrome MESHD. We report the first confirmed case TRANS of COVID-19 with concomitant Guillain-Barre Syndrome in Colombia MESHD. In patients with Guillain-Barre Syndrome MESHD, several viral and bacterial pathogens have been found in case-control studies but there are do not clarity in what triggers the immune-mediated destruction of nerves. More studies are needed to determine possible association among COVID-19 exposure and Guillain-Barre Syndrome MESHD.

    Machine learning for COVID-19 detection and prognostication using chest radiographs and CT scans: a systematic methodological review

    Authors: Michael Roberts; Derek Driggs; Matthew Thorpe; Julian Gilbey; Michael Yeung; Stephan Ursprung; Angelica I. Aviles-Rivero; Christian Etmann; Cathal McCague; Lucian Beer; Jonathan R. Weir-McCall; Zhongzhao Teng; James H. F. Rudd; Evis Sala; Carola-Bibiane Schönlieb

    id:2008.06388v1 Date: 2020-08-14 Source: arXiv

    Background: Machine learning methods offer great potential for fast and accurate detection and prognostication of COVID-19 from standard-of-care chest radiographs (CXR) and computed tomography (CT) images. In this systematic review we critically evaluate the machine learning methodologies employed in the rapidly growing literature. Methods: In this systematic review we reviewed EMBASE via OVID, MEDLINE via PubMed, bioRxiv, medRxiv and arXiv for published papers and preprints uploaded from Jan 1, 2020 to June 24, 2020. Studies which consider machine learning models for the diagnosis or prognosis of COVID-19 from CXR or CT images were included. A methodology quality review of each paper was performed against established benchmarks to ensure the review focusses only on high-quality reproducible papers. This study is registered with PROSPERO [CRD42020188887]. Interpretation: Our review finds that none of the developed models discussed are of potential clinical use due to methodological flaws and underlying biases. This is a major weakness MESHD, given the urgency with which validated COVID-19 models are needed. Typically, we find that the documentation of a model's development is not sufficient to make the results reproducible and therefore of 168 candidate papers only 29 are deemed to be reproducible and subsequently considered in this review. We therefore encourage authors to use established machine learning checklists to ensure sufficient documentation is made available, and to follow the PROBAST (prediction model risk of bias assessment tool) framework to determine the underlying biases in their model development process and to mitigate these where possible. This is key to safe clinical implementation which is urgently needed.

    Machine learning for COVID-19 detection and prognostication using chest radiographs and CT scans: a systematic methodological review

    Authors: Michael Roberts; Derek Driggs; Matthew Thorpe; Julian Gilbey; Michael Yeung; Stephan Ursprung; Angelica I. Aviles-Rivero; Christian Etmann; Cathal McCague; Lucian Beer; Jonathan R. Weir-McCall; Zhongzhao Teng; James H. F. Rudd; Evis Sala; Carola-Bibiane Schönlieb

    id:2008.06388v2 Date: 2020-08-14 Source: arXiv

    Background: Machine learning methods offer great potential for fast and accurate detection and prognostication of COVID-19 from standard-of-care chest radiographs (CXR) and computed tomography (CT) images. In this systematic review we critically evaluate the machine learning methodologies employed in the rapidly growing literature. Methods: In this systematic review we reviewed EMBASE via OVID, MEDLINE via PubMed, bioRxiv, medRxiv and arXiv for published papers and preprints uploaded from Jan 1, 2020 to June 24, 2020. Studies which consider machine learning models for the diagnosis or prognosis of COVID-19 from CXR or CT images were included. A methodology quality review of each paper was performed against established benchmarks to ensure the review focusses only on high-quality reproducible papers. This study is registered with PROSPERO [CRD42020188887]. Interpretation: Our review finds that none of the developed models discussed are of potential clinical use due to methodological flaws and underlying biases. This is a major weakness MESHD, given the urgency with which validated COVID-19 models are needed. Typically, we find that the documentation of a model's development is not sufficient to make the results reproducible and therefore of 168 candidate papers only 29 are deemed to be reproducible and subsequently considered in this review. We therefore encourage authors to use established machine learning checklists to ensure sufficient documentation is made available, and to follow the PROBAST (prediction model risk of bias assessment tool) framework to determine the underlying biases in their model development process and to mitigate these where possible. This is key to safe clinical implementation which is urgently needed.

    Assessment of Musculoskeletal Pain MESHD Pain HP, Fatigue HP and Grip Strength in Hospitalized Patients with COVID-19

    Authors: Sansin Tuzun; Aslinur Keles; dilara okutan; Tugbay Yildiran; Deniz Palamar

    doi:10.21203/rs.3.rs-56548/v1 Date: 2020-08-10 Source: ResearchSquare

    IMPORTANCE Coronavirus disease 2019 (COVID-19) is an emerging disease that was declared as a pandemic by WHO. Although there are many retrospective studies to present clinical aspects of the COVID-19, still the involvement of the musculoskeletal system has not been deeply investigated.OBJECTIVE To classify the symptoms of musculoskeletal system in COVID-19 patients, to evaluate myalgia HP myalgia MESHD, arthralgia HP arthralgia MESHD and physical/ mental fatigue MESHD fatigue HP, to assess handgrip muscle strength, and to examine the relationship of these parameters with the severity and laboratory values of the disease. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study was performed at the IUC-Cerrahpaşa Pandemic Clinic. Hospitalized 150 adults TRANS with laboratory and radiological confirmation of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) according to WHO interim guidance were included in the study. Data were recorded from May 15,2020, to June 30, 2020.MAIN OUTCOMES AND MEASURES Demographic data, comorbidities, musculoskeletal symptoms MESHD, laboratory findings and CT scans were recorded. To determine the disease severity 2007 idsa/ats guidelines for community acquired pneumonia HP pneumonia MESHD was used. Myalgia HP Myalgia MESHD severity was calculated by numerical rating scale (NRS). Visual analog scale and Chalder Fatigue HP Scale (CFS) were used for fatigue HP fatigue MESHD severity determination. Handgrip strength (HGS) was measured by Jamar hand dynamometer.RESULTS 103 patients (68.7%) were nonsevere and 47 patients (31.3%) were severe. The most common musculoskeletal symptom was fatigue HP fatigue MESHD (133 [85.3%]), followed by myalgia HP myalgia MESHD (102 [68.0%]), arthralgia HP arthralgia MESHD (65 [43.3%]) and back pain HP back pain MESHD (33 [22.0%]). Arthralgia HP Arthralgia MESHD, which was mostly notable at wrist (25 [16.7%]), ankle (24 [16.0%]) and knee (23 [15.3%]) joints, showed significant correlation with disease severity. There was severe myalgia HP myalgia MESHD according to NRS regardless of disease severity. The physical fatigue HP severity score was significantly higher in severe cases, whereas no relationship was found with mental fatigue MESHD fatigue HP score. Female patients with severe infection HP infection MESHD had lower grip strength with a mean value of 18.26 kg (P= .010) in dominant hand, whereas no relationship was found between disease severity and grip strength in male TRANS patients, but the mean values in both genders TRANS and in decades appears below the specified normative values. Lactate dehydrogenase (LDH) level and lymphocyte count were significantly correlated with lower grip strength. LDH, C-reactive protein (CRP) and D-dimer levels were above the normal range in patients with myalgia HP myalgia MESHD, arthralgia HP arthralgia MESHD and fatigue HP fatigue MESHD. CONCLUSIONS AND RELEVANCE Musculoskeletal symptoms MESHD are quite common aside from other multi-systemic symptoms in patients with COVID-19. Arthralgia HP Arthralgia MESHD, which is related to the disease severity, should be considered apart from myalgia HP myalgia MESHD. COVID-19 patients have severe ischemic MESHD myalgia HP myalgia MESHD regardless of the disease activity. Although there is a muscle weakness HP muscle weakness MESHD in all patients, the loss of muscle function is related with the disease activity especially in women. Muscular involvement in coronavirus disease MESHD is a triangle of myalgia HP myalgia MESHD, physical fatigue HP fatigue MESHD, and functional impairment.

    Clinical manifestations of patients with Coronavirus Disease MESHD 2019 (COVID- 19) attending at hospitals in Bangladesh

    Authors: Md. Shahed Morshed; Abdullah Al Mosabbir; Prodipta Chowdhury; Sheikh Mohammad Ashadullah; Mohammad Sorowar Hossain

    doi:10.1101/2020.07.30.20165100 Date: 2020-08-01 Source: medRxiv

    Bangladesh is in the rising phase of the ongoing pandemic of the coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV-2). The scientific literature on clinical manifestations of COVID-19 patients from Bangladesh is scarce. This study aimed to report the sociodemographic and clinical characteristics of patients with COVID-19 in Bangladesh. We conducted a cross-sectional study at three dedicated COVID-19 hospitals. The severity of the COVID-19 cases was assessed based on the WHO interim guidance. Data were collected only from non-critical COVID-19 patients as critical patients required immediate intensive care admission making them unable to respond to the questions. A total of 103 RT-PCR confirmed non-critical COVID-19 patients were enrolled. Most of the patients (71.8%) were male TRANS. Mild, moderate and severe illness were assessed in 74.76%, 9.71% and 15.53% of patients respectively. Nearly 52.4% of patients had a co-morbidity, with hypertension HP hypertension MESHD being the most common (34%), followed by diabetes mellitus HP diabetes mellitus MESHD (21.4%) and ischemic MESHD heart disease MESHD (9.7%). Fever HP Fever MESHD (78.6%), weakness MESHD (68%) and cough HP (44.7%) were the most common clinical manifestations. Other common symptoms included loss of appetite (37.9%), difficulty in breathing (37.9%), altered sensation of taste or smell (35.0%), headache HP headache MESHD (32%) and body ache MESHD (32%). The median time from onset of symptom TRANS to attending hospitals was 7 days (IQR 4-10). This study will help both the clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-19 patients in Bangladesh.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.